BioCentury
ARTICLE | Finance

Viehbacher navigates to Waypoint

Why Christopher Viehbacher joined Gurnet Point Capital

June 29, 2015 7:00 AM UTC

Although Christopher Viehbacher will take over life sciences fund Gurnet Point Capital at the all-time peak of biotech markets, the former Sanofi CEO still sees opportunities for investments and buyouts.

Gurnet was launched in 2013 as the first U.S. fund of Waypoint Capital, the investment vehicle of the Bertarelli family, which ran Serono S.A. until it sold its 64.5% stake in 2007 as part of Merck KGaA's (Xetra:MRK) CHF16.6 billion ($13.2 billion) acquisition of the Swiss company...